PDF herunterladen
Aktuelle Kardiologie 2012; 1(04/05): 276-280
DOI: 10.1055/s-0032-1324820
Übersichtsarbeit
Georg Thieme Verlag KG Stuttgart · New York

Die dilatative Kardiomyopathie – ein Update

Dilated Cardiomyopathy – An Update
B. Meder
1   Abteilung Innere Medizin III, Kardiologie, Angiologie und Pulmologie, Universitätsklinik Heidelberg
,
K. S. Frese
1   Abteilung Innere Medizin III, Kardiologie, Angiologie und Pulmologie, Universitätsklinik Heidelberg
,
H. A. Katus
1   Abteilung Innere Medizin III, Kardiologie, Angiologie und Pulmologie, Universitätsklinik Heidelberg
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
16. Oktober 2012 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

Die dilatative Kardiomyopathie (DCM) ist eine der häufigsten Herzmuskelerkrankungen. In einem signifikanten Anteil handelt es sich um eine familiäre Erkrankung, weshalb eine gezielte Familienanamnese erfolgen sollte und eine genetische Untersuchung Betroffener und deren Angehöriger erwogen werden müssen. Die genetische Charakterisierung erleichtert sowohl die Differenzialdiagnose als auch eine Risikostratifizierung der betroffenen Patienten.

Durch die oft progrediente Verschlechterung der systolischen Herzkraft spielen außer einer leitliniengerechten medikamentösen Herzinsuffizienztherapie immer häufiger interventionelle Verfahren eine wichtige Rolle. Neben der Herztransplantation haben daher insbesondere die kardiale Resynchronisationstherapie, die Mitralklappenrekonstruktion und mechanische Kreislaufunterstützungssysteme die Prognose der schweren DCM verbessert.

Abstract

Dilated cardiomyopathy (DCM) is a major cause of heart failure and sudden cardiac death in the young. In a significant proportion it shows familial aggregation, hence structured assessment of the familyʼs pedigree and genetic testing of familial cases and relatives must be considered. The genetic characterization facilitates both differential diagnosis and risk stratification of patients.

Due to the often progressive deterioration of systolic function, besides optimal pharmaceutical treatment interventional therapies are more important than ever. Hence, not only heart transplantation, but also cardiac resynchronization therapy, mitral valve repair and cardiac assist devices are able to improve the prognosis of end-stage DCM.

Schlüsselwörter

dilatative Kardiomyopathie - DCM - Genetik - CRT

Key words

dilated cardiomyopathy - DCM - genetics - CRT
 

  • Literatur

  • 1 Doval HC, Nul DR, Grancelli HO et al. Nonsustained ventricular tachycardia in severe heart failure. Independent marker of increased mortality due to sudden death. GESICA-GEMA Investigators. Circulation 1996; 94: 3198-3203
    CrossrefPubMedGoogle Scholar
  • 2 Franke J, Zugck C, Wolter JS et al. A decade of developments in chronic heart failure treatment: a comparison of therapy and outcome in a secondary and tertiary hospital setting. Clin Res Cardiol 2011; 101: 1-10
    PubMedGoogle Scholar
  • 3 Lehrke S, Lossnitzer D, Schob M et al. Use of cardiovascular magnetic resonance for risk stratification in chronic heart failure: prognostic value of late gadolinium enhancement in patients with non-ischaemic dilated cardiomyopathy. Heart 2011; 97: 727-732
    CrossrefPubMedGoogle Scholar
  • 4 Ismail TF, Prasad SK, Pennell DJ. Prognostic importance of late gadolinium enhancement cardiovascular magnetic resonance in cardiomyopathy. Heart 2012; 98: 438-442
    CrossrefPubMedGoogle Scholar
  • 5 Muntoni F, Cau M, Ganau A et al. Brief report: deletion of the dystrophin muscle-promoter region associated with X-linked dilated cardiomyopathy. N Engl J Med 1993; 329: 921-925
    CrossrefPubMedGoogle Scholar
  • 6 Malhotra R, Mason PK. Lamin A/C deficiency as a cause of familial dilated cardiomyopathy. Curr Opin Cardiol 2009; 24: 203-208
    CrossrefPubMedGoogle Scholar
  • 7 Van Rijsingen IA, Arbustini E, Elliott PM et al. Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. J Am Coll Cardiol 2012; 59: 493-500
    CrossrefPubMedGoogle Scholar
  • 8 Herman DS, Lam L, Taylor MR et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med 2012; 366: 619-628
    CrossrefPubMedGoogle Scholar
  • 9 Meder B, Haas J, Keller A et al. Targeted next-generation sequencing for the molecular genetic diagnostics of cardiomyopathies. Circ Cardiovasc Genet 2009; 4: 110-122
    PubMedGoogle Scholar
  • 10 Hassel D, Dahme T, Erdmann J et al. Nexilin mutations destabilize cardiac Z-disks and lead to dilated cardiomyopathy. Nat Med 2009; 15: 1281-1288
    CrossrefPubMedGoogle Scholar
  • 11 Refaat MM, Lubitz SA, Makino S et al. Genetic variation in the alternative splicing regulator, RBM20, is associated with dilated cardiomyopathy. Heart Rhythm 2012; 9: 390-396
    CrossrefPubMedGoogle Scholar
  • 12 Villard E, Perret C, Gary F et al. A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. Eur Heart J 2011; 32: 1065-1076
    CrossrefPubMedGoogle Scholar
  • 13 Friedrichs F, Zugck C, Rauch GJ et al. HBEGF, SRA1, and IK: Three cosegregating genes as determinants of cardiomyopathy. Genome Res 2009; 19: 395-403
    PubMedGoogle Scholar
  • 14 Meder B, Haas J, Keller A et al. Targeted next-generation sequencing for the molecular genetic diagnostics of cardiomyopathies. Circ Cardiovasc Genet 2011; 4: 110-122
    CrossrefPubMedGoogle Scholar
  • 15 Haas J, Katus HA, Meder B. Next-generation sequencing entering the clinical arena. Mol Cell Probes 2011; 25: 206-211
    CrossrefPubMedGoogle Scholar
  • 16 Moretti M, Merlo M, Barbati G et al. Prognostic impact of familial screening in dilated cardiomyopathy. Eur J Heart Fail 2010; 12: 922-927
    CrossrefPubMedGoogle Scholar
  • 17 Abdo AS, Kemp R, Barham J et al. Dilated cardiomyopathy and role of antithrombotic therapy. Am J Med Sci 2010; 339: 557-560
    PubMedGoogle Scholar
  • 18 Okutucu S, Oto A. Risk stratification in nonischemic dilated cardiomyopathy: Current perspectives. Cardiol J 2010; 17: 219-229
    PubMedGoogle Scholar
  • 19 Theuns DA, Smith T, Hunink MG et al. Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronization therapy in patients with ischaemic or non-ischaemic heart disease: a systematic review and meta-analysis. Europace 2010; 12: 1564-1570
    CrossrefPubMedGoogle Scholar
  • 20 Smith T, Theuns DA, Caliskan K et al. Long-term follow-up of prophylactic implantable cardioverter-defibrillator-only therapy: comparison of ischemic and nonischemic heart disease. Clin Cardiol 2011; 34: 761-767
    CrossrefPubMedGoogle Scholar
  • 21 Gervais R, Leclercq C, Shankar A et al. Surface electrocardiogram to predict outcome in candidates for cardiac resynchronization therapy: a sub-analysis of the CARE-HF trial. Eur J Heart Fail 2009; 11: 699-705
    CrossrefPubMedGoogle Scholar
  • 22 Mcleod CJ, Shen WK, Rea RF et al. Differential outcome of cardiac resynchronization therapy in ischemic cardiomyopathy and idiopathic dilated cardiomyopathy. Heart Rhythm 2011; 8: 377-382
    CrossrefPubMedGoogle Scholar
  • 23 Castellant P, Fatemi M, Orhan E et al. Patients with non-ischaemic dilated cardiomyopathy and hyper-responders to cardiac resynchronization therapy: characteristics and long-term evolution. Europace 2009; 11: 350-355
    CrossrefPubMedGoogle Scholar
  • 24 Matsumoto K, Tanaka H, Okajima K et al. Relation between left ventricular morphology and reduction in functional mitral regurgitation by cardiac resynchronization therapy in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 2011; 108: 1327-1334
    CrossrefPubMedGoogle Scholar
  • 25 Feldman T, Foster E, Glower DD et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 2011; 364: 1395-1406
    CrossrefPubMedGoogle Scholar